Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis -33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort--Autoimmune disease-modifying activity demonstrated by targeting FcgRIIb (CD32b)--Clinical trial for rare autoimmune disorder IgG4-related disease (IgG4-RD) planned for 2015--Conference call today at 8:30 a.m. ET-

MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported top-line results from a Phase 1b/2a study for XmAb®5871. In addition to the study's primary objective of characterizing safety and tolerability, the data showed promising activity in patients with rheumatoid arthritis (RA), including multiple DAS28-CRP remissions and ACR50 and ACR70 responses. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary XmAb immune inhibitor Fc domain that targets...